Sponsor Dossier
Boehringer Ingelheim
Sponsor Dossier for Boehringer Ingelheim. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACTILYSE
- Brand: ATROVENT
- Brand: ESOVYND
- Brand: GIOTRIF
- Brand: GLYXAMBI
- Brand: JARDIAMET
- Brand: JARDIANCE
- Brand: METALYSE
- Device (sponsor): Medicine administration kit, oral
- Device (sponsor): Medication transfer set
- Device (sponsor): Medication transfer set
- Device (sponsor): Medicine administration kit, <specify>
- Device (sponsor): Inhaler, aerosol, portable
- Device (sponsor): Unclassified
- Device (sponsor): Unclassified
About
Boehringer Ingelheim is an Australian Private Company with ABN 52000452308, registered in NSW, with active entity status. The company trades under the names Boehringer Ingelheim Pty Ltd, Paladin Pharma, Altoria Pharma, and Zenith Pharma.
Portfolio
Boehringer Ingelheim has 26 brands on the ARTG, of which 22 are indexable and 20 carry a Product Information document. 14 brands are PBS-listed, 11 have a PBAC outcome on record, and 10 have an AusPAR on record. Notable brands include ACTILYSE, ATROVENT, ESOVYND, GIOTRIF, GLYXAMBI, JARDIAMET, JARDIANCE, METALYSE, MICARDIS, MOBIC, OFEV, PRADAXA.
Therapeutic focus
— Respiratory: 9 brands — Cardiology: 7 brands — Endocrinology: 5 brands — Neurology: 1 brand — Musculoskeletal: 1 brand — Infectious Disease: 1 brand — Haematology: 1 brand — Oncology: 1 brand
PBS footprint
14 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2025-05-01, across 11 brands with a PBAC outcome on record. The latest AusPAR is 2024-08-01, across 10 brands with an AusPAR on record.